key: cord-1017773-pfe7nvbm
authors: Kim, Nicole S.; Maliyar, Khalad; Oliveira, Luciana; O’Toole, Ashley; Gooderham, Melinda J.
title: Real‐world experience of dupilumab in the treatment of moderate‐to‐severe atopic dermatitis
date: 2020-08-09
journal: Int J Dermatol
DOI: 10.1111/ijd.15053
sha: a6f67bcf567691090c60a31053d372e57150ae4e
doc_id: 1017773
cord_uid: pfe7nvbm

nan

adverse events (AEs). An evaluation of overall response to treatment was done with a description of patient satisfaction and clinical response recorded in the patient's clinical chart at each visit.

Baseline characteristics of 34 patients in this study cohort are outlined in Table 1 . Of the 34 patients analyzed, 20 (58.9%) reported an AE (Table 2 ). There was an average of 1.5 AE 1.6

AEs reported per patient on dupilumab. The most frequently reported AEs included nasopharyngitis (n = 4, 11.8%) and conjunctivitis (n = 4, 11.8%). Dupilumab was discontinued in two patients: one due to persistence of the disease and the other due to an AE of the development of swollen glands, otalgia, and myalgias. Our results confirm that dupilumab provides promising clinical improvement in patients suffering from moderate-to-severe AD in real-world practice. In regards to safety, in this cohort, 11.8% of patients reported nasopharyngitis and 11.8% reported conjunctivitis compared to 15.7% and 8.0%, respectively, in clinical trials. 10 Moreover, 5.9% of patients reported injection site reactions compared to 13.2% of patients in clinical trials. Our main study limitation is that of small numbers, and because our study was conducted in a busy community practice, it was not practical to measure objective indices of efficacy such as eczema area and severity index (EASI) and Scoring AD (SCORAD) for each patient at every visit. There are also inherent limitations of chart reviews which can be a threat to both internal bias (confounding bias) and external validity.

In conclusion, in real-world practice, our evaluation of dupilumab indicates that its use has both a lack of serious adverse effects and provides clinical improvement in a majority of patients with moderate-to-severe AD. Furthermore, in the context of the 

Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebocontrolled, phase 3 trial

Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments: a randomised, placebo-controlled, dose-ranging phase 2b trial

Dupilumab: a review of its use in the treatment of atopic dermatitis

Dupilumab therapy provides clinically meaningful improvement in patient-reported outcomes (PROs): a phase IIb, randomized, placebo-controlled, clinical trial in adult patients with moderate to severe atopic dermatitis (AD)

Dupilumab: short-term effectiveness and security in real clinical practice -a retrospective multicentric study

Real-world experience of dupilumab treatment for atopic dermatitis in adults: a retrospective analysis of patients' records

Effectiveness of dupilumab treatment in 95 patients with atopic dermatitis: daily practice data